Seres Therapeutics Current Ratio 2013-2021 | MCRB

Seres Therapeutics current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Seres Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.23B $0.06B 4.00
2021-03-31 $0.25B $0.05B 5.27
2020-12-31 $0.27B $0.05B 5.79
2020-09-30 $0.31B $0.05B 6.73
2020-06-30 $0.07B $0.04B 1.64
2020-03-31 $0.08B $0.04B 1.83
2019-12-31 $0.10B $0.05B 2.18
2019-09-30 $0.09B $0.04B 2.12
2019-06-30 $0.11B $0.04B 2.53
2019-03-31 $0.07B $0.04B 1.63
2018-12-31 $0.09B $0.04B 2.20
2018-09-30 $0.08B $0.04B 2.04
2018-06-30 $0.10B $0.04B 2.76
2018-03-31 $0.13B $0.04B 3.60
2017-12-31 $0.16B $0.03B 4.90
2017-09-30 $0.18B $0.03B 6.54
2017-06-30 $0.18B $0.03B 6.86
2017-03-31 $0.19B $0.03B 7.06
2016-12-31 $0.20B $0.03B 6.51
2016-09-30 $0.21B $0.03B 6.54
2016-06-30 $0.22B $0.03B 7.94
2016-03-31 $0.31B $0.03B 12.36
2015-12-31 $0.21B $0.01B 19.01
2015-09-30 $0.22B $0.01B 45.89
2015-06-30 $0.09B $0.01B 16.68
2015-03-31 $0.11B $0.00B 30.59
2014-12-31 $0.11B $0.01B 22.39
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 1.62
2012-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.570B $0.033B
Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86